-1 	|BT| (S (ADVP (RB Additionally)) (, ,) (NP (NP (NP (NN transcription) (NN factor) (JJ early) (NN growth) (NN response-1)) (PRN (-LRB- -LRB-) (NP (NN Egr-1)) (-RRB- -RRB-))) (NN gene) (ADJP (RB transcriptionally) (VBN activated)) (NN level) (NP (NP (JJ non-steroidal) (JJ anti-inflammatory) (NN drug)) (PRN (-LRB- -LRB-) (NP (NN NSAID)) (-RRB- -RRB-)))) (: -) (NP (NP (NP (VBN activated) (NN gene-1)) (PRN (-LRB- -LRB-) (NP (NN NAG-1)) (-RRB- -RRB-))) (NN protein)) (ADVP (RB also)) (VP (VBD elevated) (NP (JJ PTX-2-treated) (NN Hep3B) (NN cell)))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 41:A11 52:E02 580:D12.776.260.158.500 796:D27.505.696.663.850.014.040.500 1272:D03.438.759.758.824.651.700|ES| 2:1 4:1 5:1 9:1 10:1 14:1 19:1 94:1 102:1 163:1 185:1 191:1 249:1 487:1 756:1 1128:1 1662:1 1854:1 1859:1 2367:1 2795:1 4068:1 4497:1 4498:1 4499:1 4500:1 4501:1 4502:1

-1 	|BT| (S (NP (NP (NP (JJ Epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN tyrosine) (NN kinase) (NN inhibitor) (NN erlotinib)) (VP (VBP show) (SBAR (S (NP (JJ potent) (NP (NP (NN antitumor) (NN activity) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD approved) (NP (NNP Food) (NNP Drug) (NNP Administration) (JJ second) (JJ third) (NN line) (NN treatment) (NN NSCLC))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1

-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN ACR) (NN GW4064)) (ADVP (RB cooperatively)) (VP (VBP inhibit) (SBAR (S (NP (NN RXRalpha) (NN phosphorylation)) (, ,) (VP (VBP modulate) (NP (NP (NN expression) (JJ FXR-regulated) (NN gene)) (, ,) (S (ADVP (RB thus)) (VP (VBG resulting) (NP (NN induction) (NN apoptosis) (NN inhibition) (NN growth) (NN HCC) (NN cell))))))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383 142:I01.880.604 155:G05.355.310 972:G02.111.087.677|ES| 2:1 9:1 19:1 89:1 94:1 101:1 102:1 103:1 115:1 384:1 441:1 658:1 736:1 796:1 1334:1 1370:1 3426:1 4017:1 4503:1 4504:1 4505:1 4506:1 4507:1

-1 	|BT| (S (NP (JJ Quantitative) (JJ real-time) (NN RT-PCR) (NN analysis)) (VP (VBD showed) (SBAR (S (NP (NN troglitazone)) (VP (VBD down-regulated) (NP (NN Skp2) (NN mRNA) (NN level))))))) |ET| |BS|111:D13.444.735.544 142:I01.880.604 257:E05.393.620.500.706 351:A17.360 507:D12.776.157.743|ES| 19:1 132:1 249:1 325:1 661:1 874:1 1148:1 1283:1 1785:1 3732:1 4508:1

-1 	|BT| (S (NP (DT This) (NN research)) (VP (VBZ provides) (NP (NN evidence) (NN tea)) (, ,) (NP (ADVP (RB particularly)) (NP (VBN administered) (NN combination) (NN sulindac)) (, ,) (NP (PP (ADJP (RB highly) (JJ effective)) (S (VP (VBG inhibiting) (NP (NP (NP (JJ intestinal) (NN neoplasia) (NN male) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN min)) (-RRB- -RRB-))) (NN mouse)) (PP (IN via) (NP (JJ direct) (JJ indirect) (NN effect) (NN beta-catenin/APC) (NN pathway)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 102:C04.588.274.476.411 122:C14.280.383 251:D02.455.426.559.847.486.875 644:H01.770.644 645:H01.770.644|ES| 2:1 10:1 14:1 19:1 38:1 52:1 75:1 109:1 280:1 383:1 530:1 596:1 626:1 640:1 807:1 815:1 869:1 880:1 1402:1 1639:1 1891:1 2336:1 2378:1 2379:1 2380:1 2381:1 2382:1 2383:1

-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NP (VBN isolated) (NN colon) (NNS CSCs)) (PRN (-LRB- -LRB-) (NP (NP (JJ positive) (NN CD44)) (, ,) (NP (NN CD133) (NN ALDH1b1) (NN marker))) (-RRB- -RRB-))) (VP (VBG functioning) (NP (NP (NN p53) (JJ shRNA-attenuated) (NN p53)) (VBN treated) (NN PA) (CD 5.0) (NN mug/ml)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 46:A03.556.124.526.356 52:E02 158:D23.101 556:C11.768.175 1127:Z01.107.757.656 1273:D13.150.650.700|ES| 2:1 10:1 12:1 14:1 19:1 113:1 233:1 534:1 652:1 1099:1 1581:1 1629:1 1653:1 1691:1 1966:1 3943:1 4509:1 4510:1 4511:1 4512:1

-1 	|BT| (S (NP (NNP UNLABELLED) (: :)) (S (VP (TO To) (VP (VB evaluate) (NP (NN possibility) (JJ radionuclide) (NN gene) (NN therapy) (NN imaging) (JJ hepatocellular) (NN carcinoma) (NN cancer))))) (, ,) (VP (VBD investigated) (NP (NP (NP (NN iodine) (NN accumulation) (JJ human) (JJ hepatocellular) (NN carcinoma) (NN cell) (NN line)) (, ,) (NP (NN SK-Hep1))) (, ,) (NP (NP (NN transfer) (JJ human) (NN sodium) (NN iodide) (NN symporter)) (PRN (-LRB- -LRB-) (NP (NN hNIS)) (-RRB- -RRB-))) (NP (NN gene))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 104:C04.557.470.200.025.255 225:E05.337 265:C04.557.470.200 967:D01.248.497.158.490 1017:E01.370.350 1274:D01.268.380.400 1275:D01.496.749|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 94:1 104:1 130:1 264:1 303:1 304:1 343:1 403:1 407:1 828:1 890:1 1644:1 2120:1 2266:1 3561:1 4513:1 4514:1 4515:1 4516:1 4517:1 4518:1

-1 	|BT| (SINV (SBAR (IN Whether) (S (NP (NP (JJ single) (NN cell)) (NP (NP (ADJP (RB immunohistochemically) (JJ positive)) (NN glutathione) (NN S-transferase) (NN P1-1)) (PRN (-LRB- -LRB-) (NP (NN GSTP1-1)) (-RRB- -RRB-)))) (VP (VBD induced) (NP (JJ female) (NN mouse) (NN liver) (NN DEN))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Hatayama) (FW et) (FW al.)) (, ,) (NP (NN Carcinogenesis)) (, ,) (CD 14) (, ,) (CD 537-538) (, ,) (NP (CD 1993))) (-RRB- -RRB-)) (NP (NP (NN precursor) (VBD initiated) (NN cell) (JJ preneoplastic) (NN focus)) (, ,) (NP (NN importance) (NN chemical) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 242:A03.620 642:M01.975 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 897:Z01.252.245.500.375 962:A11.148.378 1276:D08.811.913.225.500.500|ES| 2:1 10:1 14:1 19:1 52:1 94:1 233:1 412:1 836:1 900:1 1404:1 1431:1 1438:1 1440:1 1660:1 1875:1 1900:1 2124:1 2744:1 2745:1 2846:1 3167:1 4519:1 4520:1 4521:1 4522:1 4523:1 4524:1 4525:1 4526:1 4527:1 4528:1

-1 	|BT| (S (NP (CD 1,25) (NN D)) (VP (VBD inhibited) (SBAR (S (NP (NN MYC) (NN gene) (NN expression)) (VP (VBD accelerated) (NP (NN protein) (NN turnover))))))) |ET| |BS|7:D12.776 122:C14.280.383 155:G05.355.310 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 665:N04.452.677.680|ES| 4:1 9:1 19:1 115:1 365:1 472:1 1391:1 2424:1 4529:1

-1 	|BT| (S (S (NP (CD 1,25) (NN D)) (VP (VBD inhibited) (SBAR (S (NP (NP (NN transcription) (JJ c-MYC-regulated) (NN gene) (NN vitro)) (, ,) (NP (JJ topical) (CD 1,25) (NN D))) (VP (VBD suppressed) (NP (NN expression) (NN c-MYC) (NN target) (CD setd8) (NN mouse) (NN skin)))))) (, ,)) (IN whereas) (S (NP (NN MXD1) (NN level)) (VP (VBD increased)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 142:I01.880.604 185:G05.360.340.024.340.375.500.791.420 209:G02.111.087.847 785:A17.815|ES| 2:1 9:1 19:1 47:1 52:1 115:1 160:1 216:1 249:1 307:1 365:1 372:1 487:1 625:1 2319:1 4529:1 4530:1 4531:1 4532:1 4533:1

-1 	|BT| (S (NP (DT A) (NN benzimidazole) (JJ derivative) (VBG exhibiting) (NN antitumor) (NN activity) (NN block) (NN EGFR) (NN HER2) (NN activity)) (VP (VBZ upregulates) (NP (NN DR5) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 122:C14.280.383 175:J01.897.280.500.269 798:D03.438.103|ES| 18:1 19:1 23:1 69:1 94:1 187:1 188:1 399:1 742:1 2153:1 2244:1 2812:1 2813:1 3755:1 3793:1

-1 	|BT| (FRAG (NP (NP (DT A) (JJ critical) (NN threshold) (NN beta-catenin) (NN level) (JJ TCF-regulated) (NN transcription) (JJ uncovered) (NN Apc)) (JJ mutation-induced) (NN effect) (NN colon) (NN epithelium)) (, ,) (PP (IN along) (NP (NN evidence) (JJ feed-forward) (NN role) (NN beta-catenin) (NN Ctnnb1) (NN gene) (NN expression) (NN CTNNB1) (NN transcription)))) |ET| |BS|3:C04.557.470.035.215.100 15:F01.829.316.616 18:G05.365.590 23:D12.776.091.249 46:A03.556.124.526.356 62:A10.272 142:I01.880.604 155:G05.355.310 209:G02.111.087.847 1277:N03.219.442|ES| 2:1 9:1 19:1 31:1 38:1 60:1 69:1 75:1 113:1 115:1 173:1 249:1 280:1 487:1 825:1 1019:1 2666:1 3344:1 4032:1 4350:1 4534:1 4535:1 4536:1

-1 	|BT| (S (NP (DT A) (VBN decreased) (NN protein) (NN level) (NN DAX-1) (NN APAP) (NN treatment)) (ADVP (RB also)) (VP (VBD enhanced) (SBAR (S (NP (NN miR-561)) (VP (VBP mimic) (NP (NN transfection) (NN HepG2) (NN cell) (JJ primary) (JJ human) (NNS hepatocytes))))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 112:D12.776.097.820 217:E05.393.350.810 262:A11.436.348 661:D02.065.199.092.040 1015:A11.251.860.180.432|ES| 4:1 5:1 19:1 36:1 69:1 94:1 202:1 249:1 344:1 385:1 546:1 567:1 746:1 894:1 3481:1 4193:1 4537:1 4538:1

-1 	|BT| (S (NP (NN Activation) (NN RXRalpha) (JJ retinoic) (NN acid)) (VP (VBD increased) (NP (NP (NN cyclin) (NN E1) (NN promoter) (NN activity)) (VP (VBG indicating) (NP (ADJP (JJ retinoic) (JJ acid-mediated)) (NN signaling)))) (S (ADVP (RB positively)) (VP (VBP control) (NP (NN cyclin) (NN E1) (NN gene) (NN expression)))))) |ET| |BS|69:G02.111.087.800 155:G05.355.310 711:D02.455.326.271.665.202.495 770:D02.455.326.271.665.202.495.818.500|ES| 9:1 19:1 47:1 83:1 87:1 115:1 195:1 289:1 399:1 743:1 1275:1 1580:1 2236:1 2704:1 3848:1 4017:1 4539:1

-1 	|BT| (S (S (NP (JJ Acute) (NN treatment) (NN B6C3F1) (NN mouse) (NN phenobarbital)) (VP (VBD resulted) (SBAR (S (NP (VBN increased) (NN level) (NN bcl-2)) (VP (VBD decreased) (NP (NN level) (NN bax) (NN protein))))))) (, ,) (NP (JJ acute) (NN treatment) (NN WY-14,643)) (VP (VBD resulted) (NP (VBN increased) (NN bcl-2) (NN BAG-1) (NN protein) (NN liver)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 54:G05.360.340.024.340.375.500.791.150 242:A03.620 342:D12.644.360.075.718.400 756:D03.383.742.698.253.650|ES| 2:1 4:1 19:1 47:1 52:1 90:1 151:1 202:1 249:1 546:1 594:1 836:1 1136:1 1893:1 2685:1 3986:1 4540:1 4541:1

-1 	|BT| (S (ADVP (RB Additionally)) (, ,) (NP (NN DNA) (NN microarray) (NNS data)) (VP (VBD indicated) (SBAR (S (NP (NN cell) (JJ cycle-related) (NN gene) (NNS cyclins) (NN CCNB1) (NN CCNA2) (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN CDKN3)) (ADVP (RB also)) (VP (VBD down-regulated) (NP (NP (NN treatment)) (NP (CC either) (NP (NN PB) (NN CF) (CD 13) (NN week))))))))) |ET| |BS|52:E02 142:I01.880.604 325:Z01.058.290.100.140 351:A17.360 979:D12.644.360.262.120.100 996:G05.360.340.024.340.220 1278:D12.644.360.262.100.200 1279:D12.644.360.225 1280:D12.644.360.262|ES| 2:1 5:1 9:1 19:1 39:1 94:1 380:1 470:1 546:1 666:1 783:1 793:1 913:1 1100:1 1283:1 1532:1 1541:1 3496:1 4068:1 4542:1 4543:1 4544:1 4545:1 4546:1 4547:1

-1 	|BT| (S (NP (NN AIMS/METHODS)) (: :) (NP (PRP We)) (VP (VBD evaluated) (NP (NP (FW vivo) (NN effect) (JJ intraperitoneal) (NN injection) (NN Ras) (NN inhibitor) (NN S-trans)) (, ,) (NP (NP (NP (JJ trans-farnesylthiosalicyclic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (S (NP (NN Ras) (NN activation) (NN development) (JJ preneoplastic) (NN liver) (NN lesion) (NN rat)) (VP (VBG receiving) (NP (NP (NP (JJ weekly) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN injection) (NNS 16weeks)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 168:E05.581 225:E05.337 226:E02.319.267.530 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 917:E02.319.267.530.490 1062:D01.029|ES| 2:1 10:1 14:1 19:1 35:1 75:1 104:1 225:1 378:1 380:1 548:1 780:1 785:1 836:1 843:1 849:1 1131:1 1275:1 1438:1 1775:1 1875:1 1952:1 3230:1 4076:1 4548:1 4549:1 4550:1 4551:1 4552:1

-1 	|BT| (NP (NP (NNS AIMS)) (: :) (S (NP (DT The) (NN aim) (NN study)) (VP (VBP examine) (NP (NN effect) (NNS NSAIDs) (NP (NN mRNA) (NN expression) (NN tumour) (NN suppressor) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)) (NN rat) (NN colon) (NN mucosa))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 111:D13.444.735.544 155:G05.355.310 206:G05.360.340.024.340.375.249 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 302:A10.615.550 796:D27.505.696.663.850.014.040.500|ES| 9:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 75:1 104:1 113:1 115:1 131:1 325:1 579:1 691:1 700:1 849:1 960:1 1011:1 1567:1 1778:1 2966:1

-1 	|BT| (S (NP (DT All) (NN result)) (VP (VBD revealed) (NP (NP (NN pterostilbene) (JJ effective) (NN antitumor) (NN agent)) (NP (RB well) (NP (JJ inhibitory) (NN effect) (NN down-regulation) (JJ inflammatory) (NN iNOS) (NN COX-2) (NN gene)) (NN expression) (NN up-regulation) (NN apoptosis) (NN mouse) (NN colon))) (, ,) (S (VP (VBG suggesting) (NP (NP (NP (NN pterostilbene)) (JJ novel) (JJ functional) (NN agent)) (ADJP (JJ capable) (S (VP (VBG preventing) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248|ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1

-1 	|BT| (S (S (PP (IN Along) (NP (NN Nrf2) (NN inhibition))) (, ,) (NP (NN trig)) (VP (VBD blocked) (NP (NP (JJ Nrf2-dependent) (NN expression) (JJ proteasomal) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN example)) (, ,) (NP (NN s5a/psmd4) (NN alpha5/psma5))) (-RRB- -RRB-)))) (VP (VBD reduced) (NP (NP (NN proteasome) (NN activity) (NN cell) (NN line)) (VP (VBN tested)))))) |ET| |BS|43:F01.145.544 94:A11.251.210 122:C14.280.383 155:G05.355.310 799:D12.776.260.615.249 1281:D05.500.562.500|ES| 2:1 9:1 10:1 14:1 19:1 94:1 103:1 115:1 264:1 399:1 452:1 2777:1 2988:1 3490:1 4355:1 4553:1 4554:1 4555:1 4556:1 4557:1 4558:1 4559:1

-1 	|BT| (S (SBAR (IN Although) (S (NP (NN study)) (VP (VBD needed) (VP (VB prove) (SBAR (S (NP (VBN increased) (NN expression) (NN Egr-1) (NN PTX-2)) (VP (ADVP (RB directly)) (VBP lead) (NP (NP (NN NAG-1) (NN induction) (NN apoptosis) (NN induction)) (NP (JJ p53-deficient) (NN Hep3B) (NN cell)))))))))) (, ,) (VP (VBP result) (SBAR (S (NP (NN study)) (VP (VBP suggest) (SBAR (S (NP (NN PTX-2)) (VP (MD may) (NP (JJ good) (NN candidate) (NN development) (JJ potential) (JJ anti-tumorigenic) (NN agent) (JJ p53-deficient) (NN tumor)))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 86:D01.268.556.435 284:N03.349.380.420 1272:D03.438.759.758.824.651.700|ES| 2:1 7:1 19:1 35:1 47:1 89:1 94:1 101:1 107:1 115:1 131:1 254:1 491:1 621:1 728:1 736:1 796:1 827:1 981:1 1243:1 1318:1 1662:1 2669:1 4498:1 4502:1 4560:1 4561:1 4562:1

-1 	|BT| (S (SBAR (IN Although) (S (NP (NP (NP (NN Mlh1)) (PRN (-LRB- -LRB-) (NP (NN G67R)) (-RRB- -RRB-))) (NN mutation)) (VP (VBD resulted) (NP (NN DNA) (NN repair) (NN deficiency) (JJ homozygous) (JJ mutant) (NN mouse))))) (, ,) (VP (VBP affect) (SBAR (S (NP (NP (JJ MMR-mediated) (JJ cellular) (NN response) (NN DNA) (NN damage)) (, ,) (PP (VBG including) (NP (NP (JJ apoptotic) (NN response) (JJ epithelial) (NN cell) (JJ intestinal) (NN mucosa) (NN cisplatin)) (, ,) (NP (NP (JJ defective) (NN Mlh1)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))) (VP (VBD remained) (NP (NP (NP (JJ normal) (NN Mlh1)) (PRN (-LRB- -LRB-) (NP (NN G67R/G67R)) (-RRB- -RRB-))) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 39:G04.299.139.160 41:A11 191:A03.556.124.369 433:F01.470.047 498:D01.210.375 526:G05.355.180 1282:C18.452.284 1283:G05.380.554|ES| 2:1 10:1 14:1 19:1 34:1 45:1 52:1 94:1 107:1 109:1 118:1 127:1 253:1 494:1 513:1 561:1 579:1 586:1 594:1 666:1 811:1 1486:1 1761:1 1848:1 1861:1 2223:1 3074:1 4563:1 4564:1 4565:1 4566:1 4567:1

-1 	|BT| (NP (NP (PP (IN Among) (NP (JJ different) (NNS chemotherapeutics))) (, ,) (NP (NN induction) (NN WT1) (NN transcription) (JJ restricted) (NN topoisomerase) (CD 2) (NN inhibitor)))) |ET| |BS|209:G02.111.087.847 382:C04.557.435.595 1284:D27.505.519.389.892.750|ES| 2:1 19:1 148:1 380:1 414:1 487:1 736:1 1000:1 1292:1 4568:1 4569:1 4570:1

-1 	|BT| (S (NP (DT An) (JJ apoptosis-related) (NN gene) (NN expression) (NN profiling) (NN analysis)) (VP (VBD provided) (SBAR (S (NP (NP (NP (NN clue) (JJ death-associated) (NN protein) (NN kinase) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN dapk1)) (-RRB- -RRB-))) (NN gene)) (VP (VBN upregulated) (NP (ADJP (JJS least) (JJ twofold)) (NN response) (NN grifolin) (NN treatment) (JJ nasopharyngeal) (NN carcinoma) (NN cell) (NN CNE1))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 41:A11 52:E02 718:E05.588.570 1285:D08.811.913.696.620.682.700.125.387 1286:E05.393.332|ES| 4:1 9:1 10:1 14:1 19:1 94:1 98:1 115:1 125:1 304:1 470:1 494:1 546:1 661:1 1015:1 1142:1 1155:1 1178:1 1331:1 2148:1 4571:1 4572:1 4573:1 4574:1 4575:1 4576:1

-1 	|BT| (VP (NP (NP (NP (NN Androgen)) (PRN (-LRB- -LRB-) (NP (NP (NN R1881)) (, ,) (NP (NN dihydrotestosterone))) (-RRB- -RRB-))) (NN treatment) (NP (NP (NN SVHUC) (VBN immortalized) (JJ normal) (JJ urothelial) (NN cell)) (ADVP (RB stably)) (VP (VBG expressing) (NP (NP (NN AR)) (PRN (-LRB- -LRB-) (NP (NN SVHUC-AR)) (-RRB- -RRB-)))))) (VP (VBD decreased) (NP (NN GATA3) (NN expression) (NN mRNA) (NN protein) (NN level))) (, ,) (VP (VBD abolished) (NP (NNS anti-androgens)))) |ET| |BS|7:D12.776 41:A11 52:E02 111:D13.444.735.544 321:A10.272.850 892:D27.505.696.399.472.161 1287:D04.808.054.040.248 1288:D06.347.065 1289:D04.808.365.415.550|ES| 2:1 4:1 10:1 14:1 19:1 94:1 115:1 118:1 202:1 249:1 325:1 478:1 546:1 810:1 1078:1 1357:1 1852:1 2152:1 4577:1 4578:1 4579:1 4580:1 4581:1 4582:1 4583:1

-1 	|BT| (S (NP (NP (JJ Antisense) (NNS oligodeoxynucleotides) (JJ human) (NN superoxide) (NN dismutase) (CD 2)) (CC and/or) (NP (JJ ectopic) (NN bcl-2) (NN overexpression))) (VP (VBD avoided) (NP (NP (NNS polyphenols)) (SBAR (S (NP (JJ chemoradiotherapy-induced) (JJ colorectal) (NN cancer) (NN elimination)) (VP (VBD showed) (NP (NP (JJ mangano-type) (NN superoxide) (NN dismutase) (NN Bcl-2) (JJ key) (NN target) (JJ molecular) (NN mechanism)) (VP (VBN activated) (NP (JJ combined) (NN application) (NN t-PTER) (NNP QUER)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079|ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1

-1 	|BT| (S (NP (JJ Arsenic)) (VP (ADVP (RB also)) (NP (NP (ADVP (RB markedly)) (NP (VBN reduced) (NN methylation)) (PP (IN within) (NP (NN ER-alpha) (NN gene) (NN promoter) (NN region)))) (, ,) (NP (VBN assessed) (JJ methylation-specific) (NN PCR)) (, ,) (NP (NP (NN reduction)) (ADVP (RB statistically)) (NP (JJ significant) (CD 8) (CD 13) (NN CpG) (NN site))) (PP (IN within) (NP (NN promoter) (NN region)))))) |ET| |BS|6:G05.360.340.024.340 36:G02.111.087.029.538 196:G02.111.570.080.689.675 448:E05.393.620.500 1110:D12.776.826.750.350.174 1158:D01.268.513.249|ES| 2:1 5:1 9:1 19:1 81:1 83:1 135:1 370:1 452:1 662:1 667:1 781:1 875:1 1003:1 1532:1 2122:1 2396:1 3823:1 3887:1 4086:1 4584:1 4585:1

-1 	|BT| (S (NP (JJ AST-induced) (NN NAG-1) (NN activation)) (VP (VBD intensified) (NP (NN PI3K) (NN inhibitor) (NN LY294002) (NN Akt) (NN inhibitor) (JJ co-treated) (JJ reversed) (NN NAG-1) (NN siRNA) (NN transfection)))) |ET| |BS|52:E02 117:D13.150.650.700 217:E05.393.350.810 378:D08.811.913.696.620.682.700.755 1042:Z01.107.757.284 1290:D08.811.913.696.620.500|ES| 19:1 225:1 351:1 380:1 746:1 1289:1 1662:1 3400:1 4352:1 4586:1 4587:1 4588:1 4589:1

-1 	|BT| (S (PP (IN At) (NP (JJ molecular) (NN level))) (, ,) (NP (NN silibinin)) (VP (VBD increased) (NP (NP (NN IGFBP-3)) (, ,) (NP (NN Cip1/p21)) (, ,) (NP (NN Kip1/p27) (NN level) (NN ERK1/2) (NN activation))) (VP (VBD decreased) (NP (NN Bcl-2))) (, ,) (NP (JJ survivin) (NN VEGF) (NN level) (NN tumor)))) |ET| |BS|8:C04 54:G05.360.340.024.340.375.500.791.150 116:D08.811.913.696.620.682.700.567.249.750 1291:D12.776.157.420.270|ES| 2:1 7:1 19:1 47:1 158:1 161:1 202:1 225:1 249:1 2066:1 2229:1 2635:1 4590:1 4591:1 4592:1 4593:1 4594:1

-1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (NP (NP (DT The) (ADJP (RB ubiquitously) (VBN expressed)) (NP (JJ basic) (JJ helix-loop-helix) (NN transcription) (NN factor) (NN ITF-2B) (JJ important) (NN role)) (NN differentiation) (NN process)) (, ,) (S (NP (NN transcription)) (VP (VBD regulated) (NP (NN beta-catenin)))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 23:D12.776.091.249 74:G04.299.151 142:I01.880.604 166:D12.776.930 209:G02.111.087.847 1292:G02.111.570.820.709.600.040.360.360|ES| 2:1 6:1 19:1 31:1 60:1 104:1 185:1 215:1 487:1 638:1 691:1 902:1 1046:1 1664:1 1777:1 1778:1 2041:1 3733:1 4595:1 4596:1

-1 	|BT| (NP (NP (NP (VBN Based) (NN finding)) (, ,) (VBP conclude) (NN matrilysin) (NN suppressor) (NN Min) (NN phenotype)) (, ,) (VP (ADVP (RB possibly)) (VBG functioning) (NP (NN capacity) (JJ independent) (NN matrix) (NN degradation)))) |ET| |BS|80:G05.695 333:D01.045 557:D02.241.081.069.600.150 937:D08.811.277.656.300.480.525.700.250 1293:G03.495|ES| 2:1 19:1 236:1 597:1 650:1 700:1 883:1 927:1 1548:1 1629:1 1968:1 3289:1 3491:1 4597:1 4598:1

-1 	|BT| (S (SBAR (IN Because) (S (NP (NN Notch) (NN signaling) (VBN implicated) (NN colon) (NN cancer) (NN tumorigenesis)) (VP (VBZ protects) (NP (NP (NN cell) (NN apoptosis)) (VP (VBG inducing) (NP (JJ prosurvival) (NN target))))))) (, ,) (VP (VBD hypothesized) (SBAR (S (NP (NP (NN inhibition) (NN Notch) (NN signaling) (NN gamma-secretase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN GSI)) (-RRB- -RRB-))) (VP (MD may) (NP (VB enhance) (NP (NN chemosensitivity) (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032|ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1

-1 	|BT| (S (NP (NNP Betaine) (NN supplementation)) (VP (VBD attenuated) (SBAR (S (NP (NN down-regulation) (NN p16)) (VP (VBD inhibited) (SBAR (S (NP (NN up-regulation) (NN c-myc)) (VP (VBD induced) (NP (NNP DEN) (JJ dose-dependent) (NN manner)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-)))))))))) |ET| |BS|85:G02.111.087.225 122:C14.280.383 142:I01.880.604 203:G05.360.340.024.340.375.249.375 743:D02.092.877.883.077|ES| 10:1 14:1 19:1 257:1 311:1 312:1 315:1 365:1 412:1 455:1 808:1 896:1 1313:1 1668:1 1875:1 2567:1 2824:1 4599:1

-1 	|BT| (S (NP (JJ Biochemical) (NN analysis) (NN liver) (NN tissue)) (VP (VBD revealed) (NP (NN induction) (NN p66) (NN protein) (NN ethanol)) (, ,) (SBAR (IN whereas) (S (NP (JJ p66-deficient) (NN liver)) (VP (VBD responded) (NP (NP (NN alcohol) (JJ significant) (NN upregulation)) (NP (JJ mitochondrial) (JJ antioxidant) (NN enzyme) (NN MnSOD)))))) (, ,) (NP (ADJP (RB nearly) (JJ absent)) (NN control) (NN mouse)))) |ET| |BS|7:D12.776 11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 249:G05.355.315.800 339:G02.111.087.880 700:D27.505.519.217 730:D08.811 751:D02.033.375 822:D02.033|ES| 2:1 4:1 19:1 52:1 135:1 272:1 275:1 289:1 372:1 374:1 661:1 736:1 836:1 1126:1 2004:1 2388:1 2521:1 3440:1 3710:1 4600:1 4601:1 4602:1 4603:1 4604:1 4605:1

-1 	|BT| (S (VP (VBG Blocking) (NP (NP (NN activation) (NN Notch) (NN signaling) (NN GSI34)) (VP (VBN sensitized) (NP (NP (NN cell) (NN chemotherapy) (JJ synergistic) (NN oxaliplatin)) (, ,) (NP (NN 5-FU)) (, ,) (NP (NN SN-38))))))) |ET| |BS|41:A11 69:G02.111.087.800 122:C14.280.383 151:E02.319 560:D03.383.742.698.875.404|ES| 2:1 19:1 94:1 195:1 225:1 256:1 495:1 598:1 2012:1 2308:1 2543:1 4606:1 4607:1 4608:1

-1 	|BT| (NP (NP (NP (NN BTG3) (NN tumor) (NN suppressor) (NN gene) (NN promoter) (NN demethylation)) (, ,) (NP (NN histone) (NN modification) (NN cell) (NN cycle) (NN arrest)) (NP (NN genistein) (JJ renal) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375|ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1

-1 	|BT| (NP (NP (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (NP (NN Ha-ras) (NN mutation) (JJ undetectable) (NN tumor) (NN mouse)) (VP (VBN treated) (NP (NP (NN DEN/PB)) (PRN (-LRB- -LRB-) (NP (CD 0/32)) (-RRB- -RRB-))))) (, ,) (NP (NP (QP (RB approximately) (CD 80)) (NN %)) (-LRB- -LRB-) (CD 37/46) (-RRB- -RRB-) (NN tumor) (NN group)) (NP (VBD showed) (NN beta-catenin) (NN mutation))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 52:E02 216:Z01.107.084.900.425 491:D27.505.259.500 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 34:1 52:1 60:1 132:1 369:1 573:1 747:1 1099:1 1392:1 1843:1 1868:1 2300:1 4183:1 4609:1 4610:1 4611:1

-1 	|BT| (NP (NP (NN Calcium) (NN chloride)) (, ,) (NP (NN DFMO) (NN piroxicam)) (NP (NP (VBD increased) (NN protein) (NN mRNA) (NN level) (NN p16)) (PP (IN along) (NP (NN sulindac)))) (NP (VBD increased) (NN protein) (NN level) (NN p27)) (, ,) (NP (NN mRNA))) |ET| |BS|7:D12.776 111:D13.444.735.544 203:G05.360.340.024.340.375.249.375 251:D02.455.426.559.847.486.875 1294:D01.146.300 1295:D12.125.068.665.340 1296:D02.886.665.500|ES| 2:1 4:1 19:1 47:1 249:1 325:1 869:1 1124:1 1313:1 2666:1 2788:1 4612:1 4613:1 4614:1

-1 	|BT| (NP (NP (NP (NN Calcium) (NN chloride)) (, ,) (NP (NN DFMO)) (, ,) (NP (NP (NN piroxicam) (NN sulindac)) (VP (VBN administered) (NP (CD 7) (NN day)))) (VP (VBD decreased) (SBAR (S (NP (JJ mitotic) (NN index)) (VP (VBD reduced) (NP (NN protein) (NN mRNA) (NN level) (NN c-myc) (NN colon) (NN tumor)))))))) |ET| |BS|7:D12.776 51:C04.588.274.476.411.307.180 111:D13.444.735.544 212:E01.370.225.500.385.500 251:D02.455.426.559.847.486.875 1294:D01.146.300 1295:D12.125.068.665.340 1296:D02.886.665.500|ES| 2:1 4:1 7:1 19:1 113:1 202:1 249:1 325:1 452:1 455:1 720:1 721:1 869:1 988:1 2336:1 2788:1 4078:1 4612:1 4613:1 4614:1

-1 	|BT| (S (NP (NN Cdh1) (NN knockdown) (NN siRNA)) (VP (VP (VBD reversed) (NP (JJ salinomycin-induced) (NN Skp2) (NN downregulation) (NN p27Kip1) (NN upregulation)) (, ,) (S (VP (VBG indicating) (NP (NN salinomycin)))) (VP (VBZ activates) (NP (NP (NN APC)) (PRN (-LRB- -LRB-) (NP (NN Cdh1)) (-RRB- -RRB-))))) (: -) (NP (NN Skp2-p27Kip1) (NN pathway)))) |ET| |BS|3:C04.557.470.035.215.100 85:G02.111.087.225 117:D13.150.650.700 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 507:D12.776.157.743|ES| 2:1 10:1 11:1 14:1 19:1 301:1 351:1 383:1 464:1 524:1 595:1 1126:1 1785:1 2236:1 4352:1 4615:1 4616:1 4617:1 4618:1

-1 	|BT| (S (S (NP (NNP Celecoxib)) (VP (VBP induce) (NP (JJ significant) (NN autophagy) (NN U87MG-PFT)))) (, ,) (NP (NP (NN U87MG-E6) (NN U373MG) (NN cell)) (, ,) (S (VP (VBP lack) (NP (JJ functional) (NN p53)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 390:G04.299.139.399 684:D02.065.884.247|ES| 2:1 12:1 19:1 94:1 135:1 243:1 415:1 1317:1 2475:1 3937:1 4619:1 4620:1 4621:1

-1 	|BT| (S (NP (NN Celecoxib)) (VP (VBD induced) (NP (NP (NN G1-phase) (NN cell) (NN cycle) (NN arrest)) (, ,) (NP (VBN accompanied) (NP (NN p21) (NN activation) (NN U87MG) (NN cell)))))) |ET| |BS|41:A11 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 94:1 225:1 412:1 601:1 602:1 1135:1 2475:1 2801:1 4622:1 4623:1

-1 	|BT| (S (NP (NN Celecoxib)) (VP (VBZ inhibits) (NP (NN glioblastoma) (NN cell) (NN viability) (NN induction) (NN DNA) (NN damage)) (, ,) (S (VP (VBG leading) (NP (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest)) (JJ p53-dependent) (NP (NN autophagy)) (, ,) (NP (NN apoptosis))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 86:D01.268.556.435 108:G04.299.316 122:C14.280.383 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 88:1 89:1 94:1 309:1 601:1 602:1 615:1 639:1 666:1 670:1 736:1 1317:1 1848:1 2186:1 2475:1

-1 	|BT| (S (NP (NN Cell) (NN cycle) (NN analysis)) (VP (VBD showed) (SBAR (S (NP (NN MK-801)) (VP (VBD induced) (NP (NP (NN G1) (NN cell) (NN cycle) (NN arrest)) (S (NP (JJ down-regulating) (NN cyclin) (NN D1)) (VP (VBG up-regulating) (NP (NN p27)))))))))) |ET| |BS|150:Z01.542.248.960 206:G05.360.340.024.340.375.249 209:G02.111.087.847 215:D12.644.360.262.150.100 351:A17.360 353:G04.299.134 463:C23.550.210.870 1076:G04.299.134.109.249 1297:D02.455.426.559.847.181.384.380|ES| 2:1 7:1 9:1 19:1 94:1 132:1 412:1 487:1 601:1 602:1 661:1 670:1 700:1 715:1 743:1 744:1 1124:1 1256:1 1334:1 1618:1 1876:1 3097:1 3264:1 4094:1 4624:1 4625:1 4626:1 4627:1

-1 	|BT| (S (NP (NN Cell) (NN proliferation)) (ADVP (RB significantly)) (VP (VBD inhibited) (, ,) (SBAR (S (NP (NN apoptosis)) (VP (VBD induced) (NP (NP (NN area) (NN GST-P) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN focus) (NNP Valerian) (NN group)) (VP (VBN associated) (NP (NN suppression) (NN c-myc)))) (, ,) (NP (NP (NN Mafb)) (, ,) (NP (NP (NN cyclin) (NN D1) (NN induction) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN Waf1/Cip1)) (-RRB- -RRB-))) (, ,) (NP (NN p53) (NN Bax) (NN mRNA) (NN expression)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 111:D13.444.735.544 122:C14.280.383 183:G04.299.233.750 215:D12.644.360.262.150.100 292:Z01 342:D12.644.360.075.718.400 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 1298:D12.776.260.108.500.061.500 1299:D12.644.360.225.500 1300:E05.318.308.112|ES| 2:1 10:1 12:1 14:1 19:1 89:1 115:1 124:1 169:1 299:1 325:1 365:1 412:1 455:1 736:1 743:1 744:1 1135:1 1431:1 2300:1 2453:1 3057:1 3058:1 3059:1 4080:1 4094:1 4628:1 4629:1 4630:1

-1 	|BT| (NP (NP (JJ Chemopreventive) (NN agent)) (VP (VBD reported) (S (NP (NN mechanism) (VBG targeting) (NN epigenome)) (VBP include) (NP (NN micronutrient)) (-LRB- -LRB-) (NP (NP (NP (NN folate)) (, ,) (NP (NP (NN selenium)) (, ,) (NP (JJ retinoic) (NN acid))) (, ,) (NP (NN Vit))))))) |ET| |BS|224:D03.438.733.631.400 770:D02.455.326.271.665.202.495.818.500 833:D27.505.696.706.018 835:D27.505.696.377.605 935:D01.268.185.850|ES| 2:1 10:1 19:1 162:1 616:1 728:1 778:1 993:1 1275:1 2704:1 2973:1 3284:1 3972:1 4631:1 4632:1 4633:1

-1 	|BT| (NP (NP (JJ Chemopreventive) (NN agent)) (VP (VBD reported) (S (NP (NN mechanism) (VBG targeting) (NN epigenome)) (VBP include) (NP (NN micronutrient)) (-LRB- -LRB-) (NP (NP (NP (NN folate)) (, ,) (NP (NP (NN selenium)) (, ,) (NP (JJ retinoic) (NN acid))) (, ,) (NP (NN Vit))))))) |ET| |BS|36:G02.111.087.029.538 56:D02.455.426.559.389.657.715 224:D03.438.733.631.400 399:D12.776.660.470 433:F01.470.047 595:G07.203.650.240 652:D20.215.784.249 674:B01.650.510.956 684:D02.065.884.247 692:D02.455.326.146.485.222.222 737:D04.808.105.225.272.962 741:D03.383.663.283.909 770:D02.455.326.271.665.202.495.818.500 833:D27.505.696.706.018 835:D27.505.696.377.605 935:D01.268.185.850 944:D03.383.663.283.266.450.400.375 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400 1059:H01.158.703 1295:D12.125.068.665.340 1301:B01.650.940.800.575.100.842.500.444 1302:D02.455.426.559.389.140.450.582 1303:D02.455.426.559.847.562.050.650 1304:B01.650.940.800.575.100.610.100 1305:D27.505.954.122.085.255.135 1306:D27.505.954.122.085 1307:D02.241.081.114.750 1308:D10.212.302.380.410 1309:D02.241.081.114 1310:D02.033.623 1311:D12.125.068.555 1312:D02.886.489 1313:D02.092.782 1314:D08.811.913 1315:D01.875|ES| 2:1 10:1 14:1 19:1 69:1 81:1 154:1 162:1 380:1 399:1 503:1 616:1 728:1 778:1 993:1 1275:1 1380:1 1712:1 2070:1 2085:1 2379:1 2386:1 2433:1 2458:1 2498:1 2530:1 2566:1 2594:1 2630:1 2704:1 2807:1 2973:1 3219:1 3284:1 3314:1 3371:1 3598:1 3707:1 3758:1 3916:1 3924:1 3972:1 4229:1 4245:1 4613:1 4631:1 4632:1 4633:1 4634:1 4635:1 4636:1 4637:1 4638:1 4639:1 4640:1 4641:1 4642:1 4643:1 4644:1 4645:1 4646:1 4647:1 4648:1 4649:1 4650:1 4651:1 4652:1 4653:1 4654:1 4655:1 4656:1 4657:1 4658:1 4659:1 4660:1 4661:1 4662:1 4663:1 4664:1 4665:1 4666:1 4667:1 4668:1 4669:1 4670:1 4671:1 4672:1 4673:1 4674:1

-1 	|BT| (S (NP (JJ Colonic) (NN adenocarcinoma)) (ADVP (RB rapidly)) (VP (VBD induced) (NP (NP (JJ combined) (NP (NN treatment) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine) (NN dextran) (NN sodium) (NN sulfate) (JJ male) (NN ICR) (NN mouse) (NN posse) (NN beta-catenin) (NN gene) (NN mutation)) (NN increase) (NN immunoreactivity) (NN beta-catenin)) (, ,) (NP (NN cyclooxygenase-2) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase))))) |ET| |BS|18:G05.365.590 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 46:A03.556.124.526.356 84:C04.557.470.200.025 131:D09.698.365.272.300 618:E02.186 744:D03.383.725 1316:B01.050.050.199.520.520.510|ES| 2:1 9:1 19:1 34:1 40:1 52:1 60:1 61:1 63:1 64:1 65:1 66:1 164:1 255:1 406:1 407:1 412:1 546:1 1373:1 1378:1 1402:1 2638:1 2639:1 2640:1 3048:1 3300:1 3424:1 4675:1 4676:1 4677:1

-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN curcumin)) (VP (VBZ potentiates) (NP (NP (JJ antitumor) (NN effect) (NN radiation) (NN therapy)) (JJ colorectal) (NN cancer) (VBG suppressing) (NP (NN NF-kappaB) (JJ NF-kappaB-regulated) (NN gene) (NN product))) (, ,) (NP (VBG leading) (NN inhibition) (NN proliferation) (NN angiogenesis))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745|ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1

-1 	|BT| (S (NP (NN CONCLUSION) (: :)) (NP (PRP$ Our) (NN finding)) (VP (VBP reveal) (NP (NN p53) (NN increase) (JJ human) (NN glioblastoma) (NN sensitivity) (NN celecoxib)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 36:1 40:1 104:1 607:1 658:1 927:1 1670:1 1882:1 2186:1 2807:1

-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT Both) (NP (NN sulindac) (NN etodolac))) (VP (VBD reduced) (NP (NN occurrence) (NN ACF) (VBD induced) (NN increase) (NN APC) (NN mRNA) (NN rat) (NN colon) (NN mucosa))))) |ET| |BS|3:C04.557.470.035.215.100 12:Z01.542.049 46:A03.556.124.526.356 111:D13.444.735.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 302:A10.615.550 842:N02.278.035 1317:D03.066.288.200|ES| 11:1 19:1 40:1 104:1 113:1 239:1 325:1 412:1 452:1 579:1 849:1 869:1 2282:1 2914:1 4678:1 4679:1

-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN FTS)) (VP (VBZ inhibits) (NP (NP (NN Ras)) (NN activation)))) (VP (VBZ prevents) (NP (NP (JJ preneoplastic) (NN liver) (NN nodule) (NN development)) (VP (VBG inducing) (NP (NP (NN apoptosis)) (VP (VBN transformed) (NP (NNS hepatocytes) (NN activation) (NN Fas/Fas) (NN ligand) (NN system)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 39:G04.299.139.160 122:C14.280.383 242:A03.620 262:A11.436.348 1318:D12.644.276.374.750.249|ES| 19:1 35:1 89:1 104:1 225:1 239:1 593:1 615:1 836:1 894:1 1438:1 1775:1 1835:1 1864:1 2718:1 4551:1 4680:1 4681:1 4682:1

-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NP (DT The) (JJ novel) (NN effect) (NN ROS)) (VP (VBG modulating) (NP (NP (NP (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN expression) (NN splice) (NN variant)))) (VP (MD could) (VP (VB play) (NP (JJ relevant) (NN role) (NN liver) (NN injury) (NN TNFalpha) (NN regulation)))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 142:I01.880.604 242:A03.620 259:D12.776.395.240.150.500 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 10:1 14:1 19:1 31:1 75:1 104:1 115:1 238:1 239:1 438:1 691:1 836:1 865:1 891:1 908:1 990:1 2356:1 2416:1 2435:1 4116:1 4683:1 4684:1 4685:1

-1 	|BT| (S (ADVP (RB Consistently)) (, ,) (NP (NP (NN expression) (JJ oxidative-stress-inducible) (NN gene) (NN heme) (NN oxygenase-1)) (PRN (-LRB- -LRB-) (NP (NN HO-1)) (-RRB- -RRB-))) (VP (VBD upregulated) (NP (NN liver) (JJ arsenic) (NN group)))) |ET| |BS|155:G05.355.310 716:G03.495.710 1158:D01.268.513.249 1226:E01.370.372.460 1319:D08.811.682.690.708.410.500|ES| 2:1 9:1 10:1 14:1 19:1 115:1 125:1 836:1 2300:1 4106:1 4686:1 4687:1 4688:1 4689:1 4690:1

-1 	|BT| (S (ADVP (RB Consistently)) (, ,) (VP (VBD found) (SBAR (S (NP (NN simvastatin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN p21) (NN p27) (NN expression) (NN tumor) (NN section)) (VP (VBG reducing) (NP (NP (NN Skp2) (NN expression)) (VP (VBG inducing) (NP (NN AMPK) (NN activation) (NN STAT3) (NN suppression) (NN tumor) (NN tissue))))))))))) |ET| |BS|8:C04 82:D12.644.360.024.342.300 98:A10 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900|ES| 2:1 5:1 7:1 19:1 37:1 47:1 115:1 225:1 251:1 272:1 1124:1 1135:1 1785:1 1864:1 2453:1 2679:1 3331:1 4686:1 4691:1 4692:1

-1 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NN IEX-1) (NN overexpression) (NN Colo320mut) (NN cell)) (VP (VBD caused) (SBAR (S (NP (NP (NN increase) (JJ basal) (NN TNFalpha)) (: -) (NP (JJ 5-FU-induced) (NN apoptosis)) (, ,) (NP (NN effect))) (VP (VBD triggered) (NP (NN G17) (NN treatment))))))) |ET| |BS|12:Z01.542.049 39:G04.299.139.160 41:A11 52:E02 560:D03.383.742.698.875.404 573:N05.715.350.200.650 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 19:1 40:1 75:1 89:1 94:1 152:1 546:1 760:1 2506:1 3398:1 3404:1 4184:1 4693:1 4694:1 4695:1 4696:1

-1 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NP (NN MBO-asGCS) (NN treatment)) (VP (VBD decreased) (NP (NP (NP (NN globo) (NN series) (NNS GSLs)) (PRN (-LRB- -LRB-) (NP (NP (NN Gb3)) (, ,) (NP (NN Gb4))) (-RRB- -RRB-))) (, ,) (NP (NN cSrc) (NN kinase) (JJ nuclear) (NN beta-catenin)) (, ,)))) (VP (VBD suppressed) (NP (NN MDR-1) (NN expression) (JJ dose-dependent) (NN pattern)))) |ET| |BS|23:D12.776.091.249 52:E02 469:D08.811.913.696|ES| 2:1 10:1 14:1 19:1 60:1 115:1 202:1 260:1 307:1 470:1 546:1 1256:1 1807:1 2824:1 3404:1 4697:1 4698:1 4699:1 4700:1 4701:1 4702:1 4703:1

-1 	|BT| (NP (NP (ADJP (NN Correction) (JJ malignant)) (NN behavior) (ADJP (NN tumor) (NN cell) (JJ traditional)) (JJ Chinese) (NN herb) (NN medicine) (NN restoration) (NN p53))) |ET| |BS|2:G05.360.340.024.340.375.249.385 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 788:H01.158.273.118.598.500 876:F01.145 1320:E02.190.488.585.520|ES| 7:1 12:1 19:1 94:1 802:1 2326:1 2327:1 2763:1 2764:1 4704:1 4705:1 4706:1

-1 	|BT| (S (NP (NP (NN Cr)) (PRN (-LRB- -LRB-) (NP (NNP VI)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (JJ significant) (NN increase) (NN miR-21) (NN expression)) (VBN associated) (NN inhibition) (NN PDCD4) (NN expression)))) |ET| |BS|43:F01.145.544 1321:Z01.107.084.900.182|ES| 10:1 14:1 19:1 40:1 103:1 115:1 135:1 169:1 2177:1 2506:1 4707:1 4708:1 4709:1

-1 	|BT| (S (NP (NP (JJ CRC-associated) (NN symptom) (NN patient)) (PP (VBG including) (NP (JJ intestinal) (NN bleeding) (NN anaemia)))) (ADVP (RB faithfully)) (VP (VBD mimicked) (NP (NP (NP (JJ AOM-treated) (NN MybER) (JJ transgenic) (NN mouse)) (VBN implicated) (NN hypoxia) (NN vessel) (NN leakage)) (VP (VBG identifying) (NP (ADJP (ADJP (JJ additional)) (ADJP (JJ pathogenic))) (NN role) (NN Myb)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 47:A03.556.124 50:M01.643 52:E02 99:B01.050.050.136.500 132:D02.172.080 327:G06.930 371:A07.231 1011:C23.888.852.079 1322:C15.378.071 1323:C23.550.414|ES| 19:1 31:1 52:1 109:1 120:1 285:1 561:1 977:1 980:1 1698:1 2474:1 4710:1 4711:1 4712:1 4713:1 4714:1 4715:1 4716:1 4717:1 4718:1 4719:1 4720:1 4721:1

-1 	|BT| (S (NP (NN Ctnnb1) (JJ hemizygous) (NN dose)) (VP (VP (ADVP (RB markedly)) (VBD inhibited) (NP (NN increase) (NN beta-catenin) (NN level) (NN cytoplasm) (NN nucleus)) (PP (VBG following) (NP (NN Apc) (NN inactivation) (NN colon) (NN epithelium)))) (, ,) (VP (VBD attenuated) (NP (NN expression) (JJ key) (JJ beta-catenin/TCF-regulated) (NN target) (NN gene)) (, ,) (PP (VBG including) (S (VP (VBG encoding) (NP (NP (NP (NN EphB2/B3) (NN receptor)) (, ,) (NP (NN stem) (NN cell) (NN marker) (NN Lgr5)) (, ,) (NP (NN Myc)) (, ,) (NP (VBG leading) (NN maintenance) (NN crypt) (NN compartmentalization) (NN restriction) (NN stem))) (VP (VBG proliferating) (NP (NN cell) (NN crypt) (NN base)))))))))) |ET| |BS|3:C04.557.470.035.215.100 23:D12.776.091.249 41:A11 46:A03.556.124.526.356 62:A10.272 86:D01.268.556.435 122:C14.280.383 142:I01.880.604 155:G05.355.310 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937 333:D01.045 1098:A11.284.430.214 1104:A11.284.430.106 1324:D08.811.913.696.620.682.725.400.850.650|ES| 2:1 9:1 19:1 40:1 60:1 94:1 113:1 115:1 159:1 160:1 173:1 186:1 249:1 280:1 365:1 534:1 561:1 639:1 808:1 1063:1 1106:1 1314:1 1786:1 2301:1 2396:1 2865:1 2913:1 3510:1 3873:1 4032:1 4722:1 4723:1 4724:1 4725:1 4726:1 4727:1 4728:1 4729:1 4730:1

-1 	|BT| (S (NP (NN Curcumin)) (VP (VBD suppressed) (NP (NP (NP (NN expression) (NN protein) (JJ related) (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NN bcl-2) (NN bcl-xL)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D1) (NN c-myc)) (-RRB- -RRB-))) (, ,) (NP (NP (NN tumor) (NN invasion)) (NP (NP (-LRB- -LRB-) (NN MMP-9) (NN ICAM-1) (-RRB- -RRB-) (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))) (, ,) (NP (NN microvessel) (NN density))))) |ET| |BS|7:D12.776 8:C04 54:G05.360.340.024.340.375.500.791.150 108:G04.299.316 215:D12.644.360.262.150.100 586:D08.811.277.656.300.480.205.360 692:D02.455.326.146.485.222.222 1325:D12.776.395.550.200.450 1326:A07.231.461|ES| 2:1 4:1 7:1 10:1 14:1 19:1 94:1 115:1 151:1 274:1 299:1 307:1 419:1 455:1 620:1 743:1 744:1 2066:1 2158:1 2502:1 3429:1 4731:1 4732:1 4733:1 4734:1

-1 	|BT| (S (NP (NP (NN Cyp2b20)) (, ,) (NP (NN growth) (NN arrest)) (: -) (NP (NP (JJ damage-inducible) (NN gene) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN Gadd45beta)) (-RRB- -RRB-))) (, ,) (NP (NP (ADJP (NN tumor) (NN necrosis) (NN factor) (JJ alpha-induced)) (NN protein) (CD 2) (JJ insulin-like) (NN growth) (NN factor) (NN binding) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Igfbp5)) (-RRB- -RRB-))) (NP (NN gene) (NN protein))) (VP (VP (VBD upregulated) (NP (NN oxazepam) (, ,) (NN Cyp2b20) (, ,) (NN Cyclin) (NN D1)) (, ,) (S (VP (VBG proliferating) (NP (NP (NP (NN cell) (JJ nuclear) (NN antigen)) (, ,) (NP (NN Igfbp5)) (, ,)) (NP (NP (NN Gadd45beta) (NN cell) (JJ death-inducing) (NN DNA) (NN fragmentation) (NN factor) (NN alpha) (JJ subunit-like) (NN effector)) (DT A)))))) (VP (VBD exhibited) (NP (JJR higher) (NN expression) (NN Wy-14,643) (NN treatment))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 45:G07.700.320.249 52:E02 134:G04.299.139 175:J01.897.280.500.269 198:D13.444.308 215:D12.644.360.262.150.100 583:D12.776.813 768:D12.776.660.740 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1327:D12.776.157.420.250 1328:D06.472.699.322.326.562 1329:D03.438.079.080.070.663 1330:G05.355.180.230|ES| 2:1 4:1 7:1 9:1 10:1 14:1 19:1 69:1 94:1 98:1 102:1 115:1 125:1 148:1 170:1 185:1 546:1 570:1 609:1 666:1 744:1 1030:1 1256:1 1487:1 1836:1 1972:1 2093:1 2865:1 4173:1 4257:1 4735:1 4736:1 4737:1 4738:1 4739:1 4740:1 4741:1 4742:1 4743:1 4744:1 4745:1

-1 	|BT| (S (NP (NP (NNP DCA)) (, ,) (NP (NNP TCA) (JJR lesser) (NN extent)) (NN chloroform)) (VP (VBD decreased) (SBAR (S (NP (NN methylation)) (VP (VBD increased) (NP (NN mRNA) (NN expression) (NN c-myc) (NN gene))))))) |ET| |BS|36:G02.111.087.029.538 111:D13.444.735.544 155:G05.355.310 1196:D02.455.526.439.224 1331:C06.198.439 1332:Z01.107.084.900|ES| 2:1 9:1 19:1 47:1 81:1 115:1 202:1 325:1 455:1 2805:1 4179:1 4180:1 4486:1 4746:1

-1 	|BT| (S (NP (JJ DHMEQ-treated) (NN cell)) (VP (VP (VBD exhibited) (NP (NN DNA) (NN damage))) (, ,) (VP (VBD evaluated) (NP (NN accumulation) (JJ nuclear) (NN focus) (NN phospho-H2AX))) (, ,) (S (ADVP (RB completely)) (VP (VBD reversed) (NP (NN NAC)))))) |ET| |BS|41:A11 52:E02 94:A11.251.210 155:G05.355.310 175:J01.897.280.500.269 225:E05.337 526:G05.355.180 1071:G04.434 1333:G02.111.087.750.700|ES| 2:1 9:1 10:1 14:1 19:1 94:1 115:1 264:1 325:1 346:1 412:1 494:1 609:1 622:1 666:1 774:1 780:1 1256:1 1431:1 1848:1 1912:1 2120:1 2522:1 2824:1 3223:1 3745:1 3746:1 4271:1 4352:1 4441:1 4747:1 4748:1 4749:1 4750:1 4751:1 4752:1 4753:1 4754:1

-1 	|BT| (S (NP (NP (JJ Dietary) (NN intake) (NN pterostilbene)) (, ,) (NP (NN constituent) (NN blueberry)) (, ,)) (VP (VBZ inhibits) (NP (NN beta-catenin/p65) (JJ downstream) (NN signaling) (NN pathway) (NN colon) (NN carcinogenesis) (NN rat)))) |ET| |BS|23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249|ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1

-1 	|BT| (S (NP (JJ Differential) (NN expression)) (VBN selected) (NP (NP (JJ beta-catenin/TCF-regulated) (NN gene)) (, ,) (NP (NN Myc)) (, ,)) (ADVP (JJ likely)) (VP (VBZ underlies) (NP (JJ context-dependent) (NN effect) (NN Ctnnb1) (NN gene) (NN dosage) (NN tumorigenesis)))) |ET| |BS|23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 142:I01.880.604 155:G05.355.310 280:G05.380.350|ES| 2:1 9:1 19:1 75:1 78:1 115:1 1328:1 1786:1 1905:1 2586:1 4032:1 4724:1 4755:1 4756:1 4757:1

-1 	|BT| (S (NP (NN Down-regulation) (NN Notch) (NN signaling)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (NP (NN induction)) (JJ prosurvival) (NN pathway)) (, ,) (NP (NP (ADJP (RB notably) (JJ phosphoinositide)) (NN kinase-3)) (: /) (NP (NNP Akt))) (, ,) (NP (NN oxaliplatin))))) |ET| |BS|69:G02.111.087.800 85:G02.111.087.225 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 2:1 5:1 19:1 195:1 256:1 383:1 736:1 1865:1 1944:1 2080:1 2543:1 3458:1 4758:1 4759:1

-1 	|BT| (S (NP (NP (NN Doxorubicin) (NN treatment)) (VP (VBD induced) (NP (NP (NP (NNS GCS)) (NP (NN MDR1) (NN expression) (NN tumor))) (, ,) (NP (NN MBO-asGCS) (NN treatment))))) (VP (VBD eliminated) (NP (NP (`` ``) (JJ in-vivo) ('' '') (NN growth) (JJ drug-resistant) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN NCI/ADR-RES)) (-RRB- -RRB-))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 67:D26 120:I01.409.418.750.600.480.150 136:D02.455.426.559.847.562.050.200.175|ES| 2:1 7:1 10:1 14:1 19:1 102:1 115:1 412:1 453:1 546:1 3247:1 3268:1 3269:1 4697:1 4760:1 4761:1 4762:1 4763:1 4764:1

-1 	|BT| (NP (NP (NP (NN Effect) (JJ antisense) (NN oligodeoxy) (NN nucleotide) (NN c-Myc) (NN E2F1)) (NP (VBN studied) (NP (JJ human) (NN HCC) (NN cell) (NN line))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 104:C04.557.470.200.025.255 1334:D09.408.620|ES| 19:1 36:1 94:1 264:1 401:1 441:1 824:1 1961:1 3661:1 4765:1 4766:1 4767:1

-1 	|BT| (NP (NP (NN Effect) (NN chloroform) (JJ dichloroacetic) (NN acid) (JJ trichloroacetic) (JJ acid-induced) (NN hypomethylation) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN kidney) (NN tumor) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 155:G05.355.310 242:A03.620 274:C04.588.945.947.535 1196:D02.455.526.439.224 1219:D02.241.081.018.214.500 1335:D02.241.081.018.214.750|ES| 7:1 9:1 19:1 52:1 115:1 455:1 836:1 1275:1 1717:1 2337:1 2599:1 3661:1 4107:1 4179:1 4273:1 4768:1

-1 	|BT| (NP (NP (NP (VBN Enhanced) (NN sensitivity) (NN celecoxib) (JJ human) (NN glioblastoma) (NN cell)) (: :) (NP (NP (NN Induction) (NN DNA) (NN damage)) (VP (VBG leading) (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest) (NN autophagy)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 19:1 36:1 88:1 94:1 104:1 601:1 602:1 607:1 639:1 666:1 670:1 1317:1 1848:1 2020:1 2186:1 2807:1 3466:1

-1 	|BT| (S (NP (NN Erlotinib)) (VP (VBZ induces) (NP (NP (JJ mitochondrial-mediated) (NN apoptosis)) (NP (NP (JJ human) (NN H3255) (JJ non-small-cell) (NN lung) (ADJP (NN cancer) (NN cell) (JJ epidermal)) (NN growth) (NN factor) (NN receptorL858R) (NN mutation)) (NP (JJ mitochondrial) (JJ oxidative) (JJ phosphorylation-dependent) (NN activation) (NN BAX) (NN BAK)))))) |ET| |BS|18:G05.365.590 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 110:C04.588.894.797.520.109.220.249 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 923:D06.472.317.350 1336:G02.111.087.677.550|ES| 18:1 19:1 34:1 36:1 89:1 94:1 102:1 184:1 185:1 214:1 225:1 327:1 328:1 2004:1 2583:1 2596:1 4769:1 4770:1 4771:1 4772:1 4773:1 4774:1

-1 	|BT| (S (NP (NN Expression) (NN profiling) (NN CC531) (NN colon) (NN carcinoma) (NN cell)) (VP (VBZ reveals) (NP (JJ similar) (NN regulation) (NN beta-catenin) (NN target) (NN gene) (NN butyrate) (NN aspirin)))) |ET| |BS|23:D12.776.091.249 41:A11 46:A03.556.124.526.356 140:G05.355.315 265:C04.557.470.200 670:D02.455.426.559.389.657.410.595.176 1307:D02.241.081.114.750 1309:D02.241.081.114|ES| 9:1 19:1 60:1 94:1 113:1 160:1 304:1 316:1 332:1 438:1 2148:1 2253:1 2487:1 3758:1 4775:1

-1 	|BT| (S (S (NP (NN Flavokawain) (NN B)) (ADVP (RB also)) (VP (VBP down-regulate) (NP (ADJP (NN Bcl-2) (JJ concomitant)) (NN increase) (NN Bax) (NN level)))) (, ,) (VP (VBD resulted) (NP (NN release) (NN cytochrome) (NN c)))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 342:D12.644.360.075.718.400 351:A17.360 589:E02.204.125 1337:D08.244.286.100 1338:D08.244.286.150|ES| 2:1 5:1 19:1 40:1 158:1 249:1 594:1 763:1 1159:1 1681:1 2165:1 3788:1 4630:1 4776:1 4777:1

-1 	|BT| (S (SBAR (IN For) (S (NP (NN therapy)) (VP (VBD advanced) (NP (NNP MTC))))) (, ,) (NP (NNP Food) (NNP Drug) (NNP Administration)) (ADVP (RB recently)) (VP (VBD approved) (NP (NP (NP (NN vandetanib) (NN cabozantinib) (, ,) (NN tyrosine) (NN kinase) (NN inhibitor)) (VP (VBG targeting) (NP (NNP RET)))) (, ,) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor) (NN receptor)) (, ,) (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (CC and/or) (NP (NN c-MET))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 633:I01.409.418.750.600.650.760 1339:D08.811.913.696.620.682.725.400.950 1340:D08.811.913.696.620.682.725|ES| 2:1 19:1 102:1 130:1 149:1 184:1 185:1 186:1 380:1 470:1 616:1 772:1 956:1 997:1 1251:1 2341:1 2343:1 2344:1 2345:1 2346:1 3092:1 3489:1 4778:1 4779:1 4780:1 4781:1

-1 	|BT| (NP (NP (JJ Formalin-fixed) (, ,) (NP (NP (NP (NN paraffin) (JJ wax-embedded) (JJ pre-operative) (NN biopsy)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 14)))) (-RRB- -RRB-))) (NP (NP (NP (JJ surgical) (NN resection) (NN specimen)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 40)))) (-RRB- -RRB-))) (NP (S (NP (NP (NN patient) (JJ rectal) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (JJ clinical) (NN UICC) (NN stage) (NN II/III)) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NP (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy)) (VP (VBN studied) (S (NP (NN TS) (: -))))))) (, ,) (NP (ADJP (NN TP) (: -) (, ,) (ADJP (JJ DPD-gene))) (NN expression) (JJ quantitative) (NNP TaqMan) (JJ real-time) (NN PCR) (NN laser) (NN microdissection))))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 115:E04 154:Z01.058.266.887 257:E05.393.620.500.706 333:D01.045 346:E05.393.620.500.706 347:D02.047.407 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500 1341:E01.370.225.998.221.580.500 1342:Z01.639.040 1343:D02.455.612|ES| 2:1 10:1 14:1 19:1 84:1 115:1 120:1 128:1 304:1 341:1 401:1 548:1 580:1 581:1 582:1 817:1 874:1 875:1 1129:1 1154:1 1440:1 1550:1 1984:1 1986:1 1987:1 1988:1 1989:1 3543:1 4046:1 4782:1 4783:1 4784:1 4785:1 4786:1 4787:1 4788:1 4789:1 4790:1

-1 	|BT| (S (NP (NN FoxM1) (NN expression) (NN activity) (NN cancer) (NN cell)) (VP (VBN targeted) (S (VP (VBG using) (NP (NN PPARgamma) (NN agonist) (JJ anti-neoplastic) (JJ antibiotic) (NN mithramycin)))))) |ET| |BS|8:C04 41:A11 719:D12.776.826.239.588 1303:D02.455.426.559.847.562.050.650 1306:D27.505.954.122.085|ES| 16:1 18:1 19:1 94:1 115:1 350:1 399:1 2588:1 3228:1 4658:1 4659:1 4791:1 4792:1

-1 	|BT| (S (S (S (NP (NN FTS)) (VP (VBZ abrogates) (NP (JJ DEN-induced) (NN Ras) (NN membrane) (NN activity)))) (, ,) (NP (NN increase) (NP (NP (NNP Tunel) (JJ positive) (NN cell)) (VP (VBN transformed)) (, ,) (NP (JJ GSTp-expressing) (NNS hepatocytes)) (, ,))) (VP (VBZ up-regulates) (NP (NN caspase) (CD 3) (CD 8) (NN activity)))) (, ,) (VP (VBZ induces) (SBAR (S (NP (NP (NN Fas)) (, ,) (NP (NN Fas) (NN ligand) (NN JNK) (NN phosphorylation))) (VP (VBZ occurs) (NP (RB independently) (NN TNFalpha) (NN Trail))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 41:A11 144:E05.393.475 150:Z01.542.248.960 262:A11.436.348 789:D12.644.276.374.500.800 790:D12.644.276.374.750 906:D08.811.277.656.262.500.126.350.300 972:G02.111.087.677 1318:D12.644.276.374.750.249 1344:A10.615|ES| 2:1 19:1 40:1 94:1 214:1 233:1 399:1 657:1 781:1 862:1 894:1 1775:1 1835:1 2149:1 2580:1 2735:1 3426:1 3622:1 4276:1 4551:1 4681:1 4685:1 4793:1 4794:1 4795:1 4796:1 4797:1 4798:1

-1 	|BT| (S (NP (JJ Further) (NN study)) (VP (VBD revealed) (SBAR (S (NP (ADJP (NN TFSC) (VBD induced)) (NN HCC) (NN cell) (NN apoptosis)) (VP (VBD inhibited) (NP (NP (JJ expressional) (NN level) (NN NF-kappaB) (JJ responsive) (NN gene)) (VP (VBN transplanted) (NP (NN tumor) (NN tissue))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 39:G04.299.139.160 41:A11 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 1345:A01.941 1346:A01.941|ES| 7:1 9:1 19:1 89:1 94:1 131:1 249:1 272:1 275:1 330:1 365:1 412:1 441:1 714:1 4799:1 4800:1 4801:1 4802:1

-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN calcitriol)) (PRN (-LRB- -LRB-) (NP (JJ active) (NN form) (NN vitamin) (NN D)) (-RRB- -RRB-))) (VP (VBD suppressed) (NP (NN CYP3A4) (NN expression) (VBG activating) (NN miR-627)))) |ET| |BS|189:V02.460 720:D04.808.247.222.474 721:D04.808.812.768 1347:D04.808.247.222.159.478.387.300 1348:D08.244.453.400|ES| 2:1 10:1 14:1 19:1 115:1 197:1 307:1 334:1 630:1 1958:1 2591:1 2592:1 4803:1 4804:1 4805:1

-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN PSI) (NN treatment)) (VP (VBD increased) (NP (NN level) (NN Bax)) (, ,) (SBAR (S (NP (NP (NN cytochrome) (NN c)) (, ,) (NP (VBN activated) (NN caspase-3)) (, ,) (NP (JJ active) (NN caspase-9)) (, ,) (NP (NP (VBN cleaved) (NN poly)) (PRN (-LRB- -LRB-) (NP (NN ADP-ribose)) (-RRB- -RRB-))) (NP (NN polymerase))) (VP (VBD decreased) (NP (NP (NN Bcl-2) (NN expression) (NN level)) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase-1) (: /) (CD 2) (NN activity)))))))) |ET| |BS|52:E02 54:G05.360.340.024.340.375.500.791.150 116:D08.811.913.696.620.682.700.567.249.750 342:D12.644.360.075.718.400 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1337:D08.244.286.100 1338:D08.244.286.150 1349:D08.811.277.656.262.500.126.550.900|ES| 2:1 10:1 14:1 19:1 47:1 115:1 158:1 163:1 197:1 202:1 249:1 334:1 394:1 399:1 546:1 1707:1 3788:1 4630:1 4777:1 4806:1 4807:1 4808:1 4809:1 4810:1 4811:1 4812:1 4813:1

-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN cancer) (NN cell)) (VP (VBD showed) (SBAR (S (NP (VBN increased) (NN level) (VBN activated) (NN caspase-3)) (VP (VBD increased) (NP (NN Bax) (NN Bcl-2) (NN Bax) (NN Bcl-xL) (NN ratio)) (, ,) (S (VP (VBG suggesting) (NP (NP (NN cell)) (VP (VBG undergoing) (NP (NN apoptosis))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 342:D12.644.360.075.718.400 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 18:1 19:1 47:1 89:1 94:1 132:1 158:1 163:1 249:1 334:1 1009:1 2940:1 4630:1 4807:1 4814:1 4815:1

-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN Cr)) (PRN (-LRB- -LRB-) (NP (NNP VI)) (-RRB- -RRB-))) (VP (VP (VBD induced) (SBAR (S (NP (NN inhibition) (NN PDCD4)) (VP (VBD suppressed) (NP (JJ downstream) (NN E-cadherin) (NN protein) (NN expression)))))) (, ,) (VP (VBD promoted) (NP (JJ beta-catenin/TCF-dependent) (NN transcription) (NN uPAR) (NN c-Myc))))) |ET| |BS|7:D12.776 23:D12.776.091.249 43:F01.145.544 209:G02.111.087.847 613:D12.776.395.550.200.200 1321:Z01.107.084.900.182|ES| 2:1 4:1 10:1 14:1 19:1 103:1 115:1 307:1 334:1 412:1 487:1 560:1 824:1 1912:1 2267:1 4707:1 4708:1 4709:1 4816:1 4817:1

-1 	|BT| (S (NP (NN gamma-Secretase) (NN inhibitor)) (VP (VBP abrogate) (NP (NP (JJ oxaliplatin-induced) (NN activation) (NN Notch-1) (NN signaling) (NN pathway) (NN colon) (NN cancer) (NN cell)) (VP (VBG resulting) (NP (VBN enhanced) (NN chemosensitivity)))))) |ET| |BS|41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800|ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1

-1 	|BT| (S (NP (JJ Gefitinib) (NN treatment)) (VP (VBD diminished) (NP (NP (ADJP (NP (NN phosphorylation) (NN ErbB-3)) (JJR >)) (NN EGFR)) (JJR >) (NN HER2/neu) (NN signal) (NN transducer) (NN activator) (NN transcription) (JJ dose-dependent) (NN fashion)))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 209:G02.111.087.847 250:E07.305.812 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295|ES| 19:1 187:1 487:1 546:1 859:1 860:1 861:1 901:1 1466:1 2824:1 3024:1 3426:1 4156:1 4754:1 4818:1

-1 	|BT| (NP (NP (NP (S (NP (NP (NN Gene) (NN expression) (NN analysis) (NN Bcl-2) (NN family) (NN gene)) (NP (JJ antioxidant) (NN enzyme))) (VP (VBD revealed) (NP (NP (NN t-PTER)) (CC +) (NP (NN QUER)) (NP (NN treatment))) (SBAR (S (ADVP (RB preferentially)) (VP (VBZ promotes)))))) (, ,) (NP (NN HT-29) (NN cell)) (ADVP (VBG growing) (FW vivo)) (, ,) (-LRB- -LRB-) (NP (NP (NP (-RRB- -RRB-) (NN superoxide) (NN dismutase) (CD 2) (NN overexpression)) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (RB approximately) (JJ 5.7-fold)) (, ,) (ADJP (IN via) (NN specificity))) (NN protein) (JJ 1-dependent) (NN transcription) (NN regulation)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN b)) (-RRB- -RRB-))) (NP (NP (NN down-regulation) (NN bcl-2) (NN expression)) (PRN (-LRB- -LRB-) (ADVP (RB approximately) (RB 3.3-fold)) (, ,)))) (PP (IN via) (NP (NN inhibition) (JJ nuclear) (NN factor-kappaB) (NN activation)))) (ADJP (-RRB- -RRB-))) |ET| |BS|43:F01.145.544 44:F01.829.263 52:E02 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 142:I01.880.604 155:G05.355.310 209:G02.111.087.847 210:D12.776.260.600 700:D27.505.519.217 730:D08.811 792:A11.251.210.190.475 1050:D12.776.157.125.050.060 1052:D12.776.641.750 1224:E05.318.740.872|ES| 2:1 4:1 9:1 10:1 14:1 19:1 94:1 97:1 103:1 115:1 146:1 147:1 148:1 151:1 152:1 158:1 166:1 167:1 225:1 257:1 275:1 298:1 378:1 438:1 487:1 546:1 596:1 661:1 1233:1 1256:1 1843:1 2388:1 2521:1 2702:1 2782:1 3059:1 3532:1 4819:1 4820:1 4821:1 4822:1 4823:1 4824:1

-1 	|BT| (S (NP (NP (NNS Genes)) (VP (VBG encoding) (NP (NP (NN DNA) (JJ damage-inducible) (CD 45) (-LRB- -LRB-) (NN GADD45) (-RRB- -RRB-) (NN family) (NN protein)) (, ,) (NP (NP (JJ particular) (NN GADD45g)) (PRN (-LRB- -LRB-) (NP (NN GADD45) (NN gamma)) (-RRB- -RRB-)))))) (VP (VBD down-regulated) (NP (NP (NN treatment)) (NP (CC either) (NP (NN PB) (NN CF) (CD 4) (CD 13) (NN week)))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 44:F01.829.263 52:E02 142:I01.880.604 325:Z01.058.290.100.140 351:A17.360 526:G05.355.180|ES| 2:1 4:1 10:1 14:1 19:1 39:1 97:1 319:1 485:1 546:1 666:1 783:1 1100:1 1283:1 1532:1 2389:1 3495:1 3496:1 4177:1 4725:1 4737:1 4825:1 4826:1

-1 	|BT| (S (NP (NN Genistein) (NN 5Aza-C) (NN treatment)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN promoter) (NN methylation)) (, ,) (S (VP (VBG reactivating) (NP (NN BTG3) (NN expression)))))) |ET| |BS|36:G02.111.087.029.538 52:E02 944:D03.383.663.283.266.450.400.375|ES| 2:1 19:1 81:1 83:1 115:1 124:1 202:1 546:1 3312:1 4827:1 4828:1 4829:1

-1 	|BT| (S (NP (NP (JJ Global) (NN gene) (NN expression) (NN analysis)) (NP (JJ subsequent) (JJ quantitative) (JJ real-time) (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction))) (VP (VBD revealed) (NP (NN BNF) (VBD induced) (`` `) (NP (NN AhR) (NN gene) (NN battery'Cyp) (NN 1a1)) (, ,) (NP (NN Cyp1a2)) (, ,) (NP (NN Cyp1b1)) (, ,) (NP (NN Nqo1)) (, ,) (NP (NN Aldh3a1) (NN Ugt1a6)) (RB also) (NP (NP (NN transcription) (NN factor) (JJ NF-E2-related) (NN factor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Nrf2)) (-RRB- -RRB-))) (PRN (: -) (NP (NP (VBN regulated) (NN gene) (NN Gstm1) (, ,) (NN Gpx2) (, ,) (NP (NP (NN Akr7a3) (NN Yc2)) (PRN (-LRB- -LRB-) (ADVP (RB also)) (NP (NN Nqo1)) (-RRB- -RRB-))) (, ,)) (NP (RB presumably) (JJ due) (JJ adaptive) (NN response) (JJ BNF-triggered) (JJ oxidative) (NN stress) (NN response))))))) |ET| |BS|6:G05.360.340.024.340 142:I01.880.604 155:G05.355.310 197:A01.456.505.420 257:E05.393.620.500.706 346:E05.393.620.500.706 573:N05.715.350.200.650 591:G02.111.087.847.500 705:D08.244.453.040.443 716:G03.495.710 799:D12.776.260.615.249 1351:D08.244.453.040.500 1352:D08.244.453.040.332 1353:D12.776.260.262.500.750|ES| 2:1 5:1 9:1 10:1 14:1 19:1 115:1 148:1 185:1 275:1 412:1 487:1 494:1 661:1 768:1 817:1 874:1 939:1 941:1 1319:1 2522:1 2583:1 2851:1 4037:1 4355:1 4830:1 4831:1 4832:1 4833:1 4834:1 4835:1 4836:1 4837:1 4838:1 4839:1 4840:1 4841:1 4842:1 4843:1 4844:1 4845:1 4846:1 4847:1

-1 	|BT| (S (NP (NN Glucosylceramide) (NN synthase)) (VP (VBZ upregulates) (NP (NN MDR1) (NN expression) (NN regulation) (NN cancer) (NN drug) (NN resistance) (NN cSrc) (NN beta-catenin) (NN signaling)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 142:I01.880.604 1354:G07.690.773.984.395|ES| 18:1 19:1 60:1 66:1 115:1 191:1 195:1 438:1 453:1 1094:1 2153:1 4702:1 4848:1

-1 	|BT| (NP (NP (NP (NNP Grifolin)) (, ,) (NP (JJ potent) (NN antitumour) (JJ natural) (NN product)) (VP (VBZ upregulates) (NP (NP (JJ death-associated) (NN protein) (NN kinase) (CD 1) (NN DAPK1)) (PP (IN via) (NP (NN p53) (JJ nasopharyngeal) (NN carcinoma) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 793:D20.215 1285:D08.811.913.696.620.682.700.125.387|ES| 2:1 4:1 12:1 19:1 22:1 94:1 98:1 304:1 470:1 596:1 675:1 1178:1 2153:1 2333:1 4572:1 4849:1 4850:1 4851:1

-1 	|BT| (S (NP (NP (NNS GSLs)) (, ,) (NP (JJ particular) (NN globo) (NN series) (NNS GSLs))) (VP (VBP mediate) (NP (NN gene) (NN expression) (NN MDR1) (NN cSrc) (NN beta-catenin) (NN signaling) (NN pathway)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 126:G02.111.087.800 155:G05.355.310|ES| 2:1 9:1 19:1 60:1 115:1 195:1 383:1 453:1 485:1 1601:1 1807:1 4698:1 4699:1 4702:1

-1 	|BT| (S (NP (NN GST-P) (NN gene) (NN expression) (VBN linked) (NN reporter) (NN gene)) (ADVP (RB specifically)) (VP (VBD suppressed) (NP (NP (NN cotransfection) (NN PPAR) (NN alpha) (NN expression) (NN plasmid) (NN presence) (NN peroxisome) (NN proliferator)) (, ,) (NP (NN clofibrate))))) |ET| |BS|155:G05.355.310 457:G05.360.600 536:D12.776.826.239.500 910:D02.241.081.114.968.500.500.195 912:D27.888.569.100.675 1355:G05.360.340.024.340.435|ES| 2:1 9:1 19:1 115:1 288:1 307:1 346:1 1279:1 1363:1 1597:1 1836:1 1887:1 1888:1 3058:1 3200:1 3227:1 4852:1

-1 	|BT| (FRAG (NP (NP (NP (NN H)) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NP (NN O) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-))) (RRC (ADVP (RB also)) (NP (VBN stimulated) (NP (NN expression) (NN Gadd45b) (VBN cultured) (NN cell)))))) |ET| |BS|94:A11.251.210 1356:D01.268.406.500 1357:A11.251|ES| 5:1 10:1 14:1 19:1 94:1 115:1 148:1 612:1 1232:1 4853:1 4854:1 4855:1

-1 	|BT| (S (ADVP (RB Hence)) (, ,) (NP (NN chloroform)) (VP (VBD prevented) (SBAR (S (NP (NN hypomethylation)) (VP (VBD increased) (NP (NP (NN mRNA)) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN tumor) (NN DCA)) (, ,) (S (VP (VBG enhancing) (NP (JJ DCA-promotion) (NN kidney) (NN tumor))))))))) |ET| |BS|111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224|ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1

-1 	|BT| (S (VP (VP (ADVP (RB Here)) (VP (VBP show)) (S (NP (NN Sp1)) (VP (VBP bind) (NP (NP (NN FoxM1) (NN promoter) (NN region)) (ADVP (RB positively))))) (VP (VBZ regulates) (NP (NP (NN FoxM1) (NN transcription)) (, ,) (NP (NN mithramycin)) (, ,) (NP (NN chemotherapy) (NN drug)) (S (ADVP (RB specifically)) (VP (VBP bind) (SBAR (S (NP (NP (NN GC)) (JJ rich) (NN sequence) (NN DNA)) (VP (VBZ inhibits) (NP (NN activity) (NN Sp1)))))))))) (, ,) (VP (VBZ inhibits) (NP (NN expression) (NN FoxM1))))) |ET| |BS|67:D26 122:C14.280.383 151:E02.319 196:G02.111.570.080.689.675 209:G02.111.087.847 1303:D02.455.426.559.847.562.050.650 1358:G02.111.570.080.380|ES| 2:1 19:1 83:1 115:1 191:1 293:1 399:1 400:1 429:1 487:1 495:1 554:1 603:1 615:1 666:1 667:1 1279:1 3848:1 4659:1 4791:1 4856:1 4857:1 4858:1

-1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBP describe) (NP (JJ functional) (NN characterization) (JJ novel) (NN rat) (JJ mutant) (NN model) (NN MMR) (NN gene) (NN Msh6)) (SBAR (S (ADVP (RB genetically)) (VP (VBD inactivated) (NP (JJ N-ethyl-N-nitrosourea-driven) (JJ target-selected) (NN mutagenesis))))))) |ET| |BS|6:G05.360.340.024.340 66:F01.658.293 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 259:D12.776.395.240.150.500 1359:G05.355.600 1360:D02.654.692|ES| 2:1 9:1 19:1 72:1 400:1 415:1 811:1 849:1 891:1 898:1 1735:1 2134:1 4859:1 4860:1 4861:1 4862:1 4863:1 4864:1

-1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (VBD investigated) (NP (NP (NN effect) (JJ erlotinib) (JJ apoptotic) (NN signal) (NN pathway) (NN H3255) (NN cell) (NN EGFR)) (PRN (-LRB- -LRB-) (NP (NN L858R)) (-RRB- -RRB-))) (NN mutation))) |ET| |BS|18:G05.365.590 39:G04.299.139.160 41:A11 761:G02.111.087.800|ES| 2:1 10:1 14:1 19:1 34:1 75:1 94:1 187:1 383:1 400:1 403:1 859:1 2223:1 2342:1 4770:1 4865:1

-1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NN NaB)) (ADVP (RB specifically)) (VP (VBZ represses) (NP (NP (NP (NP (NN expression) (NN MUC2) (NN gene)) (, ,) (NP (NN differentiation) (NN marker) (JJ secretory) (NN goblet) (NN cell) (NN lineage)) (, ,) (NP (NN forskolin)) (: -)) (NP (NN 12-O-tetradecanoylphorbol) (JJ 13-acetate-induced) (NN HT29) (NN cell))) (, ,) (NP (NN Cl) (CD .16) (NN E) (NN cell)) (, ,) (NP (JJ clonal) (JJ derivative) (NN HT29) (NN cell))) (VP (ADVP (RB spontaneously)) (VBZ differentiates) (NP (JJ goblet) (NN cell))))) |ET| |BS|41:A11 74:G04.299.151 155:G05.355.310 158:D23.101 301:A11.251.353 792:A11.251.210.190.475 1361:D02.455.849.291.500.510.850 1362:A03.556.124.369.320 1363:D02.455.849.291.300|ES| 2:1 9:1 19:1 94:1 115:1 212:1 215:1 347:1 400:1 417:1 534:1 643:1 1069:1 1262:1 1279:1 1506:1 2473:1 2813:1 3017:1 3759:1 4866:1 4867:1 4868:1 4869:1 4870:1

